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Background: EpCAM is highly expressed on membrane of epithelial tumor cells and has been detected as soluble/
secreted (sEpCAM) in serum of cancer patients. In this study we established an ELISA for in vitro diagnostics to measure
sEpCAM concentrations in ascites. Moreover, we evaluated the influence of sEpCAM levels on catumaxomab
(antibody) - dependent cellular cytotoxicity (ADCC).
Methods: Ascites specimens from cancer patients with positive (C+, n = 49) and negative (C-, n = 22) cytology
and ascites of patients with liver cirrhosis (LC, n = 31) were collected. All cell-free plasma samples were analyzed
for sEpCAM levels with a sandwich ELISA system established and validated by a human recombinant EpCAM
standard for measurements in ascites as biological matrix. In addition, we evaluated effects of different sEpCAM
concentrations on catumaxomab-dependent cell-mediated cytotoxicity (ADCC) with human peripheral blood
mononuclear cells (PBMNCs) and human tumor cells.
Results: Our ELISA showed a high specificity for secreted EpCAM as determined by control HEK293FT cell lines
stably expressing intracellular (EpICD), extracellular (EpEX) and the full-length protein (EpCAM) as fusion proteins. The lower
limit of quantification was 200 pg/mL and the linear quantification range up to 5,000 pg/mL in ascites as biological matrix.
Significant levels of sEpCAM were found in 39% of C+, 14% of C- and 13% of LC ascites samples. Higher concentrations
of sEpCAM were detectable in C+ (mean: 1,015 pg/mL) than in C- (mean: 449 pg/mL; p = 0.04) or LC (mean: 326 pg/mL;
p = 0.01). Soluble EpCAM concentration of 1 ng/mL significantly inhibited ADCC of PBMNCs on EpCAM overexpressing
target cells.
Conclusion: Elevated concentrations of sEpCAM can be found in a subgroup of C+ and also in a small group of
C- patients. We consider that sEpCAM levels in different tumor entities and individual patients should be evaluated prior
to applying anti-EpCAM antibody-based cancer therapies, since sEpCAM neutralizes catumaxomab activity, making therapy
less efficient.
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In cancer patients, abnormal accumulation of fluid within
the peritoneal cavity results in ascites formation and is fre-
quently accompanied by cancer cell accumulation. Such
malignancy-related ascites accounts for 10% of all ascites
cases [1]. A disturbed equilibrium between fluid production
and drainage due to lymphatic vessel obstruction, hyper-
permeability and fluid overproduction is the main reason
for accumulation of ascites fluid [2,3]. There are different
mechanisms how cancer cells can cause ascites. Some
malignancies such as ovarian cancer tend to form peri-
toneal carcinomatosis [4]. In contrast, colon, gastric, breast
and pancreatic cancer patients frequently form ascites due
to massive liver metastases with or without peritoneal
carcinomatosis [5,6]. In the clinical routine, cytological
analysis and biochemical tests are used to confirm periton-
eal carcinomatosis or portal hypertension as primary cause
for ascites [7]. Malignant ascites caused by peritoneal car-
cinomatosis is associated with a poor outcome [8,9]. In
the last decade, the understanding of the biology of ma-
lignant ascites has evolved. Markers, such as Carcinoem-
bryonic Antigen (CEA) or Vascular Endothelial Growth
Factor (VEGF) have been described to play a role in the
pathogenesis of malignancy-related ascites [10-12]. Fre-
quently, these markers correlate with malignancy and
increase the sensitivity of cytology analysis, which is ap-
proximately 58 to 75% to predict peritoneal carcinoma-
tosis [13,14].
EpCAM is a tumor-associated membrane marker
overexpressed in various epithelial malignancies and it
has been reported to enhance tumor signaling and pro-
liferation [15-18]. EpCAM can undergo regulated intra-
membranous proteolysis (RIP) thereby, translocating
the intracellular domain to the nucleus and shedding
the extracellular domain to the extracellular compart-
ment [17]. Consequently, the soluble variant of the
extracellular domain of EpCAM (EpEX) has been found
in sera of cancer patients [19]. EpEX has been shown
to support invasion processes of breast carcinoma cells
by supporting c-jun signaling [20]. EpEX has been de-
tected by different ELISA-systems in serum samples of
healthy and cancer patients, but no accurate reference
levels have been determined so far [21,22]. Due to its
broad expression in most frequent epithelial cancers,
EpCAM became an attractive antigen for targeted ther-
apies. However, most EpCAM-targeting agents did not
hold promise [23] and further studies on predictive bio-
markers are necessary to privilege the right patient col-
lectives for EpCAM-targeted therapies [24]. EpCAM
gene expression has been observed in cancer cells of
approximately 75% of patients with malignant ascites
[25] and therefore, the EpCAM-targeting antibody
catumaxomab was approved in 2009 by the European
Union for the intraperitoneal treatment of patientssuffering from malignant ascites. Catumaxomab is a tri-
functional antibody binding to EpCAM on epithelial-
like tumor cells and CD3+ T cells and can activate with
its Fc part monocytes and NK cells. Catumaxomab can
lower ascites level and prolong the puncture-free sur-
vival of cancer patients and increase their quality of life
[26]. Actually, there are no reliable data on the levels of
sEpCAM in patients with malignancy-related ascites.
Therefore, we analyzed and quantified soluble EpCAM
(sEpCAM) in a series of ascites samples. To guarantee
specificity and accuracy we developed a sandwich ELISA
system based on human recombinant EpCAM spiked
into ascites as biological matrix. The ELISA system was val-
idated according to “Guidance for Industry - Bioanalytic
Method Validation” for measurement in ascites as bio-
logical matrix. Our data gave evidence that sEpCAM
can be found in 39% of ascites samples with positive
cytology in concentrations significantly higher than in
ascites samples with negative cytology or specimens
from patients with liver cirrhosis.
To study effects of sEpCAM on catumaxomab activity,
we performed antibody-dependent cell-mediated cyto-
toxicity (ADCC) assays in vitro. Our in vitro assay con-
firmed that sEpCAM concentrations found in the C+




Ascites specimens from 102 patients from the period
between 2011 and 2013 were retrieved from the local
bio-bank repository. Ascites samples without anticoag-
ulants were centrifuged at 2,000 x g for 10 minutes to
separate cellular components from the fluid and cell
free supernatants (plasma) were stored at −20°C. This
retrospective analysis was approved by the ethic com-
mittee of Merano (I) after oral and written informed
consents of patients (ethics protocol Nr. 16/2011).
Generation of lentiviral expression plasmids
The plasmids EpCAM-YFP, EpICD-YFP and YFP in the
pEYFP-N1 vector backbone were a generous gift of Dr.
Olivier Gires and are described by Maetzel et al. [17]
The extracellular part of EpCAM with membrane an-
chor (EpEX-TM) was cloned by amplifying the frag-
ment by the use of KOD polymerase (Novagen) and
specific forward (5-TTA GTG AAC CGT CAG ATC
CGC TAG C) and reverse primers (5-GGC GAC CGG
TGA AAT AAC CAG CAC AAC). PCR fragments were
digested with Nhe-I, Age-I (NEB) and ligated into the
predigested p-EYFP-N1 vector (Nhe-I, Age-I, NEB) by
the use of the Quick ligation Kit (NEB). Open reading
frames were cut out by Nhe-I and Not-I (NEB), polished
with Klenow (NEB) and ligated into the pENTR-11
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and Eco RV (NEB) and polished with Klenow. All amp-
lified and purified pENTR-11 vectors were sequenced for
correct orientation and exclusion of incorporated muta-
tions. pENTR-11 vectors were site-specifically recombined
with the pLenti6-V5 DEST vector (Invitrogen) using the
Gateway LR Clonase II Pus Enzyme Mix (Invitrogen). The
resulting pLenti6 DEST vectors with the EpCAM-YFP,
EpEX-YFP, EpICD-YFP and YFP open-reading frames (all
amino acid sequences are provided in the Additional file 1:
Figure S1) were transformed and propagated in One-Shot
Stabl3 bacteria (Invitrogen).
Generation of lentiviral particles
Lentiviruses were produced in HEK293FT cells by trans-
fecting cells with the pDEST6 vectors and helper plasmid
mix (ViraPower, lentiviral support kit, Invitrogen) using Li-
pofectamine 2000. Lentiviral titers were determined by real
time PCR and quantification of woodchuck hepatitis virus
posttranscriptional response element expression (WPRE-
for: 5-ACTGACAATTCCGTGGTGTT; WPRE-rev: 5-AG
ATCCGACTCGTCTGAGG).
Generation of HEK293FT cell lines with different EpCAM
domains
Wild type HEK293FT cells were purchased from the
ATCC and propagated in DMEM high glucose medium
containing 10% bovine calf serum (Hyclone) and 100
IU/mL penicillin, 100 μg/mL streptomycin and 2 mM
glutamine (all PAA Laboratories GmbH). HEK293FT cell
lines were lentivirally transfected (pDEST6) and stable
cell lines selected with 2.5 μg/mL blasticidin (Invitro-
gen). Transgenic cell lines expressing the reporter YFP
after 2 weeks of selection were named HEK EpCAM-YFP,
HEK EpEX-YFP, HEK EpICD-YFP and HEK YFP.
Generation of recombinant human EpCAM
The EpCAM cDNA (NM_002354, Openbiosystems) was
subcloned into the p3x FLAG CMV 14 expression vector
(SIGMA Biochemicals) by the use of primers amplifying
the extracellular domain of EpCAM (EpCAM-for: 5-TAA
GAT ATC CGG CGC GCG CGC AGC; EpCAM-rev: 5-C
CG TCT AGA TTT TAG ACC CTG CAT) and the KOD
polymerase (Calbiochem). PCR products were purified
(PCR-Wizard, Promega) and cloned into the expression
vector by the use of Eco-RV, Xba-I and the Quick Ligase
Kit (all NEB).
Thereafter, ligated constructs were transformed into che-
mocompetent Top10 cells (Invitrogen), and propagated for
large scale production. Plasmids were purified by the Midi-
Prep Kit (Qiagen) and sequenced for correct fusion to the
C-terminal FLAG tag.
Plasmids were transfected into HEK293FT (Invitrogen)
cells using Lipofectamin 2000 (Invitrogen). For recombinantprotein production transfected HEK293FT cells were
cultivated in serum-free Ex-cell ACF medium (SIGMA
Biochemicals) for 4 days. Supernatants of HEK293FT
were prepared by high speed centrifugation (10,000 x g,
20 min, 4°C) and sterile filtered by the use of a 0.2 μm
filter (Millipore). Next, recombinant FLAG-fusion pro-
tein was purified by affinity chromatography and
FLAG-M2 agarose beads (SIGMA Biochemicals). The
protein was eluted from column under native condi-
tions by an excess of 3xFLAG peptide (SIGMA Bio-
chemicals). Thereafter, protein was dialyzed against
phosphate-buffered saline (Fresenius), purity analyzed
by SDS-PAGE with Page Blue Protein staining (Thermo
Scientific) and quantified by the QuanitPro TM BCA
Assay kit (SIGMA Biochemicals).
Western/dot blot analysis
Twenty μg of protein extract were denatured, separated
by a 4-15% SDS-PAGE (Criterion TGX, Bio-Rad) and
transferred to nitrocellulose membrane (Whatman).
After blocking the membrane in 5% non-fat milk pow-
der dissolved in PBS with 0.1% Tween, membranes
were incubated in 0.5% non-fat milk powder at 4°C
overnight with 0.1 μg/mL final concentration of detec-
tion antibody (BAF960), 0.1 μg/mL final concentration
of capture antibody (MAB9601) or 0.1 μg/mL final con-
centration of mouse anti-human EpCAM (clone C-10,
SCBT). Afterwards, membranes were incubated with a
HRP-conjugated rabbit anti-mouse IgG (Dako Cytoma-
tion) for capture antibody and a HRP-conjugated rabbit
anti-goat IgG (Dako Cytomation) for detection anti-
body, respectively. Next, a dilution of 1:1,000 for 1 hour
at room temperature was prepared. After washing, a
chemoluminescent substrate (LumiGLO Reagent and
Peroxide, Cell Signaling Technology) was added to the
membranes and protein was detected in the Chemidoc
XRS station (Biorad Laboratories).
For Dot Blot analysis 10 ng of FLAG-tagged EpCAM
produced in HEK293FT cells dissolved in assay buffer
(1%BSA/PBS) or serum (n = 6, healthy probands) or asci-
tes (n = 12) were spotted onto nitrocellulose membrane.
Real-time confocal microscopy
Confocal Microscopy was performed with a spinning disk
confocal system (UltraVIEW VoX; Perkin Elmer) connected
to a Zeiss AxioObserver Z1 microscope (Zeiss). Images
were acquired with the Velocity software (Perkin Elmer)
using a 63x oil immersion objective with a numerical aper-
ture of 1.42. Images shown are z-stacks of 5 planes with a
spacing of 1 μm.
EpCAM enzyme-linked immunosorbent assay
96-well plates were coated with mouse monoclonal
antibody (R&D systems MAB9601) overnight at room
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0.05% Tween® 20 in PBS the plate was blocked with an
assay buffer (1% BSA in PBS, pH 7.2 – 7.4) for 1 hour
at room temperature. Recombinant human EpCAM stand-
ard was used in a concentration range between 75 – 5,000
pg/mL and ascites samples were measured in a dilution of
1:10 in an assay puffer and incubated for 2 hours at room
temperature. After repeated washing steps a biotin-labelled
goat-detection antibody (R&D systems, BAF960) was added
to each well and incubated for another 2 hours at room
temperature. Thereafter, streptavidin-HRP was added and
incubated in the dark for 20 minutes at room temperature.
After final washing steps, a substrate solution (1:1 mixture
of H2O2 and tetramethylbenzidine) was added to each wellFigure 1 EpCAM standard and stable control cells lines for ELISA. (A) Cooma
standard proteins (GRP78 and BAP). Purity of the EpEX was approx. 93% as de
weight marker indicates reference proteins in KDa. EpEX-FLAG (293 aa) has an
living HEK293FT cell lines expressing different EpCAM isoforms fused to YFP: E
detectable in the endoplasmatic reticulum and on cell membrane. Due to the
of living cells.and incubated in the dark for another 20 minutes at room
temperature. As stop solution 2N H2SO4 was used. Color
development was detected at a wavelength of 450 nm and
570 nm using microplate reader (TECAN, Infinite F50). A
seven point standard curve was used to calculate the
amount of EpCAM (pg/mL) in ascites samples.
Antibody-Dependent Cell-mediated Cytotoxicity (ADCC)
and flow cytometry
Catumaxomab-dependent cell-mediated cytotoxicity assay
were performed with peripheral blood mononuclear cells
(PBMNCs) and EpCAM-YFP or EpICD-YFP transfected
HEK293FT cell lines. PBMNCs were collected and isolated
from healthy donors by Lymphoprep™ (LSM-separatingssie brilliant Blue staining of PAGE gel in the presence of two different
termined by Page Blue staining and densitrometric analysis. Molecular
estimated size of 35 KDa. (B) Real-Time confocal microscopy pictures of
pCAM-YFP shows expression only on cell membrane, EpEX-TM-YFP is
lack of transmembrane region EpICD-YFP is found in cytosol and nucleus
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EpCAM-YFP and EpICD-YFP HEK293FT cells were prop-
agated in 6 well (5 × 105 cells/well). One day after,
medium was changed and replaced with fresh culture
medium, containing 10% serum and 1 ng/mL catumaxo-
mab (Neovii, Fresenius Biotech) and increasing concentra-
tions of sEpCAM (0.2 - 5 ng/mL). To obtain a 1:10 ratio
between target and effector cells 5 × 106 PBMNCs were
added into each well and cell mixtures incubated for 24 h
at 37°C. ADCC reaction was documented by a Fluores-
cence Microscope (Zeiss, Axiovert 200) by the use of the
Axiovision Software. Thereafter, all cells were detached by
accutase solution (Sigma Biochemicals), washed, resus-
pended in PBS and measured on the flow cytometer (BD
FACSCanto™ II, BD Biosciences). YFP- positive HEK cells
were detected at a wavelength of 488 nm, counted and an-
alyzed by the BD FACS DIVA software.
Human diploid fibroblasts (HDF) were purchased from
Promocell and HRT-18 cells from ATCC. All used cells
lines were authenticated by us (STR-profiling). All cell lines
were cultivated in RPMI 1640 medium (Sigma Biochemi-
cals) with 10% bovine calf serum (Hyclone) and 100 IU/mL
penicillin, 100 μg/mL streptomycin and 2 mM glutamine
(all PAA Laboratories GmbH). HDFs and HRT18 cells wereFigure 2 Specificity of EpCAM ElISA. (A) Dot Blot analysis of used detection an
assay buffer (PBS/1%BSA), serum (pool of 6 healthy donors) and ascites (pool of
with EpEX in all biological matrices used and gave low background in serum an
in established HEK-293FT cell lines expressing different variants of EpCAM or the
ELISA in cell extracts and respective supernatants. Concentrations are calculated
different HEK cell lines were calculated with regard to cell number, cultur
different human cancer cell lines under standard culture conditions (D) Conce
number, culture volume and time. HRT-18 Apo and HRT-18 Nec indicate
A23187) or necrosis (100 mM H2O2).seeded at a density of 50,000 cells/cm2 and were propagated
overnight for ADCC assays. Catumaxomab (1 ng/mL) was
pre-incubated for 30 min with a pool of EpCAM high
(5,000 pg/mL) and EpCAM low ascites (< 200 pg/mL) di-
luted 1:4 in culture medium, thereafter added to tumor
cells. After 1h of incubation freshly isolated PBMNCs were
added in a 1:10 target to effector cell ratio. Cells were
detached after 24 h and collected for staining with
Fluorescein-labeled mouse anti-human EpCAM (R&D Sys-
tems) and Annexin V apoptosis detection kit PerCp-eFluor
710 (E-Biosciences). After 20 min of staining, cells were
washed and measured on the flow cytometer (BD FACS-
Canto™ II, BD Biosciences). Percentages of apoptotic cells
were determined after gating for EpCAM +/Annexin V +
cells.Statistical analysis
For statistical analysis of data the Statistical Package for the
Social Sciences (SPSS, Chicago, IL, USA) version 11.5 and
Graph Pad Prism 5 (Graph Pad Software Inc.) were used.
Chi-square, student t-test and Mann–Whitney-test were
used. P-values below 0.05 were defined as statistically
significant.tibodies to react with spiked native recombinant EpEX standard (10 ng) in
12 negative patients). Capture and detection antibodies specifically react
d ascites (B) Detection antibodies bind specifically to EpCAM and EpEX-TM
control protein YFP (Western Blot). Results were confirmed by sandwich
for 1 μg total cellular protein extract. sEpCAM levels in supernatants of the
e volume and time. (C) Western Blot analysis of EpCAM expression in
ntrations of sEpCAM in supernatants were calculated with regard to cell
supernatants of HRT-18 cells that underwent apoptosis (100 μM
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Development of the EpCAM ELISA system with
recombinant EpCAM
We produced recombinant human EpCAM protein in hu-
man HEK293FT cell line to ensure correct folding and gly-
cosylation patterns similar to that found in human tumor
cells (protein sequence can be found in Additional file 1:
Figure S1). Recombinant EpCAM showed a purity of ap-
proximately 93% as shown by Page blue staining and densi-
trometric analyses (Figure 1A).
To analyse specificities of the antibodies used, we
generated HEK293FT cell line stably expressing differ-
ent domains of EpCAM in fusion with yellow fluores-
cent protein (YFP) and named them HEK EpCAM-YFP,
HEK EpEX-YFP, HEK EpICD-YFP and HEK YFP. This enables
us to localize all protein isoforms in living cells by con-
focal microscopy (Figure 1B).Figure 3 Measurement of sEPCAM in ascites. (A) Linear functions with rec
biological matrix. (B) Scatter dot blot analysis with 95% confidence interval of th
were significantly different between C pos. and C neg. (*p < 0.05) and betweenFor the detection of sEpCAM we used two antibodies
to establish a sandwich ELISA system. To analyze their
specificities for native 3D-EpCAM, we spiked our re-
combinant EpCAM protein in EpCAM negative ascites
and serum samples as biological matrices and tested
them in Dot Blot analysis (Figure 2A). Both capture and
the detection antibodies are recognizing recombinant
human EpCAM protein (10 ng) in EpCAM free assay
puffer, ascites and serum specimens. Furthermore, speci-
ficities of detection antibodies were tested under reducing
conditions by Western Blot analysis (Figure 2B). Detection
antibodies are recognizing specifically HEK EpCAM-YFP and
HEK EpEX-YFP, but not HEK EpICD-YFP or HEK YFP. High
amounts of EpCAM were monitored only in HEK EpCAM-YFP
and HEK EpEX-YFP cytosolic extracts and the respective
supernatants (Figure 2B). Moreover, we were able to de-
tect sEpCAM in supernatants of human epithelial-likeombinant EpCAM standard (156 pg - 5,000 pg/mL) spiked in ascites as
e three ascites etiologies (C pos., C neg., LC). Soluble EpCAM concentrations
C pos. and LC (**p < 0.05).
Table 1 Cancer entities positive or negative for tumor
cells in ascites; CUP = Carcinoma of Unknown Primary;
HCC = Hepatocellular Carcinoma
Cytology
Positive Negative
Tumor entity % (n) % (n)
Ovarian 28.7 (14) 9.1 (2)
Pancreas 14.3 (7) 9.1 (2)
Stomach 14.3 (7) 4.5 (1)
Breast 12.2 (6) 13.6 (3)
Colorectal 6.1 (3) 22.8 (5)
Lung 6.1 (3) 9.1 (2)
CUP 6.1 (3) -
HCC - 18.2 (4)
Others 12.2 (6) 13.6 (3)
Total 100 (49) 100 (22)
Table 3 Soluble EpCAM concentrations in ascites specimens:
Mean and range
Ascites origin Mean [pg/mL] Range [pg/mL]
Cytology positive (C+) 1,015 LLOQ – 7,750
Cytology negative (C-) 449 LLOQ – 6,819
Liver Cirrhosis (LC) 326 LLOQ – 3,655
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Blot analysis (Figure 2C/D). Levels were from undetect-
able (<200 pg/mL) in breast carcinoma line MDA-231
up to 5,000 pg/mL in the colorectal carcinoma line
HRT-18. Interestingly, when HRT-18 cells underwent
apoptosis or necrosis sEpCAM levels significantly de-
creased (Figure 2D).Validation of the EpCAM ELISA system
Recombinant human EpEX protein produced in HEK293FT
cells was used as standard in this EpCAM ELISA sys-
tem. A standard calibration curve was drawn to permit
quantification of soluble EpCAM in ascites (Figure 3A).
Regarding recovery rates of spiked recombinant EpCAM
we got a mean recovery rate of 93% in ascites samples







n n % n % P
Whole Samples 102 26 25.5 76 74.5
Etiology
C Positive 49 19 38.8 30 61.2 0.034
C Negative 22 3 13.6 19 86.4 0.013
Liver Cirrhosis 31 4 12.9 27 87.1 0.938
Entity
Ovarian Cancer 16 7 43.8 9 56.3
Non-Ovarian 55 15 27.3 40 72.7 0.210
Cancerquantification range of 200 to 5,000 pg/mL for ascites
samples (Figure 3A).
To validate the accuracy of our results, we analysed intra-
and interassay coefficient of variation (CV). We obtained
an intra- and interassay CV of 3.2% and 4.5%, respectively
(Additional file 2: Material 2 and 3) .Moreover, we evalu-
ated short-, long-term and the freeze-and-thaw stabilities of
ascites samples (Additional file 2: Material 4). Repeated
freezing-and-thawing cycles resulted in a mean sample deg-
radation of 5.3% (Additional file 2: Material 5). Evaluation
of long term- stability at −20°C resulted in a mean degrad-
ation of 11.2% (Additional file 2: Material 6).
Soluble EpCAM concentrations in ascites samples
In this study we collected 102 ascites samples deriving from
patients suffering from cancer (n = 71) or liver cirrhosis
(n = 31). Hence, we obtained 49 patients (69.0%) with
positive cytology (C+) and 22 (31.0%) patients with
negative cytology (C-). Table 1 shows the cancer en-
tities that produced ascites with positive and negative
cytology.
We analyzed all 102 cell-free ascites samples with our
validated EpCAM ELISA system. Twenty-six (25.5%)
samples were found to be sEpCAM positive (Table 2).
We compared than sEpCAM status between the three
ascites cohorts (Table 3, Figure 3B). Soluble EpCAM ex-
pression correlated significantly with positive cytology
(p = 0.034). In the C+ cohort sEpCAM was positive in
38.8% (n = 19). In contrast, sEpCAM showed a positivity
of only 13.6% (n = 3) in the C- cohort. The differenceTable 4 Soluble EpCAM concentrations in ascites and
respective serum samples of patients (n = 10)
Patient [Entity] Ascites [pg/mL] Serum [pg/mL]
Patient 1 [Pancreatic] < LLOQ < LLOQ
Patient 2 [HCC] < LLOQ < LLOQ
Patient 3 [NET] < LLOQ < LLOQ
Patient 4 [Ovarian] 3,477 1,977
Patient 5 [Ovarian] < LLOQ < LLOQ
Patient 6 [Pancreatic] < LLOQ < LLOQ
Patient 7 [Gastric] 2,440 765
Patient 8 [Ovarian] 5,575 2,348
Patient 9 [Gastric] < LLOQ < LLOQ
Patient 10 [Ovarian] 3,650 7,750
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from liver cirrhosis (p = 0.013). Moreover, we observed a
strong correlation of positivity in ascites and the respect-
ive serum samples (Table 4).
Analysis of neutralizing effect of sEpCAM on
catumaxomab
We hypothesized that sEpCAM in ascites could interfere
with the anti-EpCAM antibody catumaxomab used forFigure 4 Analysis of ADCC in control cell lines. Effects of sEpCAM on catum
HEK EpICD-YFP cells were incubated without or with 1 ng/mL catumaxomab toge
were efficiently killing EpCAM-YFP cells, but did not attack EpICD-YFP cells. Livin
with 1 ng/mL EpEX already inhibited catumaxomab -dependent cell mediated
(B) HEK EpCAM-YFP, and HEK EpICD-YFP cells were incubated without or wit
PBMNCs and increasing concentrations of EpEX (0, 0.2, 1, 5 ng/mL). YFP positi
control cells without catumaxomab/PBMNC incubation (100%). ADCC was reptreatment of patients. To investigate these interactions
we conducted a catumaxomab-dependent cell mediated
cytotoxicity assay (ADCC) in vitro with concentrations
of antibody used in patients (1 ng/mL) and tested in-
creasing concentrations of sEpCAM (up to 5 ng/mL as
observed in a collective of C+ patients). HEK EpCAM-YFP
and HEK EpICD-YFP were used as target cells and periph-
eral blood mononuclear cells (PBMNCs) as effector cells.
Soluble EpCAM at concentrations of 1 ng/mL wasaxomab-dependent cell mediated cytotoxicity (A) HEK EpCAM-YFP, and
ther with a 10-fold excess of human PBMNCs. PBMNCs with catumaxomab
g cells are displayed by fluorescence microscopy (left picture). Incubation
cytotoxicity on EpCAM-YFP overexpressing HEK cells. Bars indicate 100 μm.
h 1 ng/mL catumaxomab together with a 10-fold excess of human
ve events were counted by flow cytometry (488 nm) and normalized to
eated three times (Mean ± SEM).
Figure 5 (See legend on next page.)
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Figure 5 Soluble EpCAM in ascites inhibits ADCC of tumor cells. Effects of sEpCAM/EpEX on catumaxomab-dependent cell mediated cytotoxicity
(A) Colorectal carcinoma cells HRT-18 and human diploid fibroblasts (HDFs) were analyzed by Western Blot for the expression of EpCAM. (B) Flow
cytometry analysis of EpCAM expression on HRT-18 cells and HDFs. (C) HRT-18 cells were incubated with or without 1 ng/mL catumaxomab (cat.)
together with a 10-fold excess of human PBMNCs (lymphocytes and monocytes). PBMNCs with catumaxomab were efficiently killing cells, but did
not attack HRT18 cells in the presence of 5 ng/mL recombinant EpEX (upper panel). Experiments were repeated with catumaxomab and sEpCAM
positive (A pos, 5 ng/mL) and negative (A neg <200 pg/mL) ascites pools (lower panel). ADCC was inhibited in ascites samples with high sEpCAM
levels. (D) Viable tumor cells are displayed as EpCAM+/Annexin− cells after staining and analysis by flow cytometry. EpEX and ascites with high
concentrations of sEpCAM inhibited catumaxomab-dependent cell mediated cytotoxicity (Mean ± SEM).
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toxicity in HEK EpCAM-YFP cells (Figure 4A). HEK EpICD-YFP
cells served as negative control and these cells were not
lysed by catumaxomab-dependent cell- mediated cytotox-
icity, showing that catumaxomab is binding specifically to
EpEX and not other surface molecules (Figure 4A). A more
detailed analysis of ADCC by counting YFP+ cells by flow
cytometry revealed that approx. 90% of HEK EpCAM-YFP
cells were lysed without sEpCAM. (Figure 4B, left image).
HEK EpICD-YFP control cells were protected from ADCC
even without EpEX (Figure 4B, right image). In the pres-
ence of 1 ng/mL or 5 ng/mL EpEX protein nearly 50% or
95% of cells were protected from ADCC (Figure 4B, left
image).
ADCC experiments were repeated with EpCAM high
HRT-18 and human diploid fibroblasts (HDFs) having no
detectable EpCAM expression on Western Blot or flow cy-
tometry analysis (Figure 5A/B). HDFs were protected from
catumaxomab-mediated ADCC (data not shown). Catu-
maxomab mediated ADCC in HRT-18 cells was signifi-
cantly inhibited by 5 ng/mL recombinant EpEX in standard
culture medium (Figure 5C, upper panel). The same signifi-
cant inhibition could also be observed with ascites hav-
ing 5 ng/mL sEpCAM, whereas catumaxomab-mediated
ADCC of tumor cells was efficient in sEpCAM negative as-
cites (Figure 5C, lower panel). Flow cytometry analysis of
viable HRT-18 cells (EpCAM positive/Annexin negative ) re-
vealed that the fraction of viable tumor cells signifi-
cantly increased in ascites samples with high concentrations
of sEpCAM and after addition of recombinant EpEX
(Figure 5D).
Discussion
The detection of the soluble EpCAM protein in body fluids
might be used for the estimation of EpCAM high tumor
cells in malignant ascites. Catumaxomab, a bispecific (anti-
EpCAM x anti-CD3) trifunctional monoclonal antibody,
was approved by the EMA for the intraperitoneal treatment
of malignant ascites. However, the selection of patients for
this treatment is challenging. The life expectancy is often
very short and there is a need for verification of additional
parameters, like EpCAM expressing tumor cells that may
help to identify patients who benefit most from catumaxo-
mab treatment. Cytology and biochemical analysis areindispensable exams to distinguish peritoneal carcinoma-
tosis from portal hypertension [3,27]. Nevertheless, the
sensitivity of cytology testing is estimated to detect only 58-
75% of the real cases of peritoneal carcinomatosis cases
[13,14]. Furthermore, due to the low sensitivity of cytology
it could be possible that our sEpCAM positive samples of
patients with negative cytology (n = 4), are in reality pa-
tients suffering of peritoneal carcinomatosis having no de-
tectable amounts of tumor cells (false-negative cases). In
line with this hypothesis, we observed a broad difference in
samples with positive cytology compared to those with a
negative cytology. (p = 0.04). Thus, we believe that sEpCAM
levels reflect the EpCAM high tumor cell load in ascites,
but our sEpCAM ELISA fails to detect EpCAM low tumor
cells. Noteworthy, higher sEpCAM levels were found only
in 39% of patients with tumor cells in ascites. This is by far
lower than EpCAM gene expression rates described for
tumor cells of malignant effusions [25] and for cell surface
protein studies using microfluidic chips [28]. This may im-
plicate that many tumor cells in ascites have probably lost
EpCAM expression because they underwent epithelial to
mesenchymal transition (EMT, such as MDA231 cells)
and tumor cell types releasing only low amounts of sEp-
CAM into their microenvironment. Noteworthy, we found
sEpCAM also in some patients with liver cirrhosis and in
these cases (n = 4) may be a surrogate marker for liver re-
generation [29,30]. Interestingly, the Oncomine data base
search revealed a 28.7 fold-higher EpCAM gene expres-
sion in cirrhotic than normal liver tissue (data not shown).
Actually, we have evidence that soluble EpCAM can
exist in two different forms: first as variant cleaved on
the membrane of EpCAM positive tumor cells (EpEX),
second, as full-length protein (EpCAM) expressed on
tumor-derived exosomes [31]. Our measurements were
done without removal of exosomes from plasma. There-
fore, our assay is not able to distinguish between soluble
EpCAM and full-length EpCAM found in membranes of
exosome vesicles.
It should be critically mentioned, that our population
was very heterogeneous and retrospective. More patients
with ovarian cancer were in the cytology positive cohort,
whereas in the cytology negative group more patients
with colorectal cancer were analyzed. So the interpret-
ation of these data should be used with caution and
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entities. In addition, no data about therapies and survival
were obtained from these patients. In fact, our scope
was to test the diagnostic value of sEpCAM in ascites
for peritoneal carcinomatosis. Based on our findings, fu-
ture studies are on the way to evaluate the prognostic
and predictive value of high sEpCAM levels in cancer
patients, especially in catumaxomab-treated patients.
In fact, our in vitro experiments demonstrated that
sEpCAM is neutralizing the activity of catumaxomab in
concentrations that we found in a cohort of our patients.
Thus, soluble EpCAM is binding to the EpCAM-binding
Fab domain of catumaxomab and is blocking this part of
the antibody for interaction with the cell membrane of
the tumor cell.
Conclusions
Elevated concentrations of sEpCAM can be found in a
subgroup of C+ and also in a small group of C- patients.
We consider that sEpCAM levels in different tumor en-
tities and individual patients should be evaluated prior
to applying anti-EpCAM antibody-based cancer therap-
ies, since sEpCAM neutralizes catumaxomab activity,
making therapy less efficient.
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